Ken Griffin Precigen, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.27 - $1.75 $8,890 - $12,250	-7,000 Reduced 31.53%	15,200 $24,000
Q1 2024 May 15, 2024	BUY	$1.21 - $1.75 $13,794 - $19,950	11,400 Added 105.56%	22,200 $32,000
Q4 2023 Feb 14, 2024	SELL	$0.89 - $1.41 $623 - $987	-700 Reduced 6.09%	10,800 $14,000
Q3 2023 Nov 14, 2023	SELL	$1.08 - $1.85 $18,468 - $31,635	-17,100 Reduced 59.79%	11,500 $16,000
Q2 2023 Aug 14, 2023	SELL	$0.96 - $1.4 $36,096 - $52,640	-37,600 Reduced 56.8%	28,600 $32,000
Q1 2023 May 15, 2023	BUY	$0.88 - $2.19 $9,768 - $24,309	11,100 Added 20.15%	66,200 $70,000
Q4 2022 Feb 14, 2023	BUY	$1.27 - $2.26 $36,195 - $64,409	28,500 Added 107.14%	55,100 $83,000
Q3 2022 Nov 14, 2022	SELL	$1.41 - $2.79 $16,214 - $32,085	-11,500 Reduced 30.18%	26,600 $56,000

140

145M

292K

53.8K

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $204M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.